聚焦超声内囊毁损术治疗强迫症与重性抑郁障碍的长期安全性与疗效
这项1期、单中心、开放标签研究纳入难治性强迫症(n=15)和重性抑郁障碍(n=12)患者,评估磁共振引导聚焦超声内囊毁损术的长期安全性与疗效。强迫症组耶鲁-布朗强迫量表评分6个月降低23%(p=.01)、12个月降低35%(p<.0001);抑郁障碍组汉密尔顿抑郁量表评分6个月和12个月分别降低26%和25%,均未达统计学显著。未登记严重不良事件,神经心理测验未见负面效应。
要点
- 强迫症组耶鲁-布朗强迫量表评分12个月较基线降低35%(p<.0001)。
- 抑郁障碍组汉密尔顿抑郁量表评分6个月和12个月分别降低26%和25%,未达统计学显著。
- 未登记严重不良事件,神经心理测验未见负面效应。
核心结论
- 磁共振引导聚焦超声内囊毁损术在强迫症和重性抑郁障碍患者中是安全的,且在强迫症人群中尤其有效。
研究设计与样本
- 1期、单中心、开放标签研究,招募难治性强迫症和重性抑郁障碍患者。
- 在磁共振引导聚焦超声内囊毁损术后6个月、12个月和18至24个月(长期)测量结局。
- 基线和术后12个月进行神经心理测验和神经影像检查。
- 主要结局为安全性,次要结局为临床应答:强迫症定义为耶鲁-布朗强迫量表评分较基线改善≥35%,重性抑郁障碍定义为汉密尔顿抑郁量表评分较基线降低≥50%。
主要发现
- 未登记严重不良效应。
- 强迫症组(n=15)基线耶鲁-布朗强迫量表评分为31.9±1.2,6个月显著降低23%(p=.01),12个月显著降低35%(p<.0001)。
- 重性抑郁障碍组(n=12)基线汉密尔顿抑郁量表评分为24.3±1.2,6个月和12个月分别降低26%和25%,均未达统计学显著。
- 神经心理测验显示内囊毁损术无负面效应。
- 在强迫症和重性抑郁障碍队列中,临床结局与毁损灶偏侧性相关:左侧更内侧的毁损灶(强迫症,p=.08)与右侧更外侧的毁损灶(重性抑郁障碍,p<.05)分别与更强的应答相关。
关键数值与推荐
- 强迫症临床应答定义为耶鲁-布朗强迫量表评分较基线改善≥35%。
- 重性抑郁障碍临床应答定义为汉密尔顿抑郁量表评分较基线降低≥50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Magnetic resonance-guided focused ultrasound (MRgFUS) trials targeting the anterior limb of the internal capsule have shown promising results. We evaluated the long-term safety and efficacy of MRgFUS capsulotomy in patients with obsessive-compulsive disorder (OCD) and major depressive disorder (MDD). METHODS: This phase 1, single-center, open-label study recruited patients with treatment-resistant OCD and MDD. Outcomes were measured 6 months, 12 months, and 18 to 24 months (long term) after MRgFUS capsulotomy. Neuropsychological testing and neuroimaging were conducted at baseline and 12 months postoperatively. The primary outcome was safety. The secondary outcome was clinical response, defined for OCD as a ≥35% improvement in Yale-Brown Obsessive Compulsive Scale scores and for MDD as a ≥50% reduction in Hamilton Depression Rating Scale scores compared with baseline. RESULTS: No serious adverse effects were registered. In patients with OCD (n= 15), baseline Yale-Brown Obsessive Compulsive Scale scores (31.9 ± 1.2) were significantly reduced by 23% (p = .01) at 6 months and 35% (p < .0001) at 12 months. In patients with MDD (n = 12), a 26% and 25% nonsignificant reduction in Hamilton Depression Rating Scale scores (baseline 24.3 ± 1.2) was observed at 6 months and 12 months, respectively. Neuropsychological testing revealed no negative effects of capsulotomy. In the OCD and MDD cohorts, we found a correlation between clinical outcome and lesion laterality, with more medial left-placed lesions (OCD, p = .08) and more lateral right-placed lesions (MDD, p < .05) being respectively associated with a stronger response. In the MDD cohort, more ventral tracts appeared to be associated with a poorer response. CONCLUSIONS: MRgFUS capsulotomy is safe in patients with OCD and MDD and particularly effective in the former population.
引用
- Hamani C, Davidson B, Rabin JS, et al. Long-Term Safety and Efficacy of Focused Ultrasound Capsulotomy for Obsessive-Compulsive Disorder and Major Depressive Disorder. Biol Psychiatry. 2024. PMID: 39187171. doi:10.1016/j.biopsych.2024.08.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。